Asymchem Pharmaceutical Group (Tianjin) Co., Ltd. Announcement Regarding Capital Increase to a Controlled Subsidiary and Related Party Transaction
This Company and its Board of Directors guarantee the authenticity, accuracy, and completeness of the information disclosed in this report, and do not have any false records, misleading statements, or significant omissions.
I. Overview of the Transaction
(I) Summary of this Transaction
Asymchem Pharmaceutical Group (Tianjin) Co., Ltd. (hereinafter referred to as "the Company" or "Asymchem Pharmaceutical") intends to increase capital in its controlled subsidiary, Shanghai Kairui BIO Biotechnology Co., Ltd. (hereinafter referred to as "Kairui BIO"), with funds from its own capital. The Company, together with Tianjin Kairui BIO Biotechnology Industry Innovation Investment Fund (Limited Partnership) (hereinafter referred to as "Kairui BIO Fund"), Suzhou Gaoling Qirui Medical Health Industry Investment Partnership (Limited Partnership) (hereinafter referred to as "Gaoling Qirui"), and Zhuhai Hengxin Medical Health Industry Investment Partnership (Limited Partnership) (hereinafter referred to as "Hengxin Medical"), and Gaoling Tongxin (Tianjin) Enterprise Management Consulting Partnership (Limited Partnership) (hereinafter referred to as "Gaoling Tongxin"), and HAO HONG博士, will jointly invest a total of RMB 123,970 million in cash into Kairui BIO. Of this amount, RMB 94,595.5823 million will be used for capital increase by Asymchem Pharmaceutical Group, RMB 8,012.0482 million for capital increase by Gaoling Qirui, RMB 1,350.6024 million for capital increase by Hengxin Medical, and RMB 96.9076 million for capital increase by HAO HONG博士. The total capital increase after this transaction will be RMB 228,915.663 million, an increase of 83.4965% over the registered capital of RMB 323,511.244 million.
(II) This Transaction Constitutes a Related Party Transaction
(III) Deliberation Procedures for this Transaction
The Company held the Fifth Board of Directors' 5th Extraordinary Meeting on July 30, 2026, and the Fifth Board of Directors' 12th Meeting on July 30, 2026. Both meetings deliberated and approved the "Proposal on Capital Increase to a Controlled Subsidiary and Related Party Transaction." The related party transaction has been deliberated and confirmed by the relevant directors.
This capital increase transaction is subject to the approval of the shareholders' meeting. This capital increase transaction does not fall under the "Measures for the Administration of Major Asset Purchases and Sales of Listed Companies."
II. Basic Information of Other Parties Involved in this Transaction
(I) Gaoling Qirui
- Basic Information
-
Company Name: Suzhou Gaoling Qirui Medical Health Industry Investment Partnership (Limited Partnership)
-
Unified Social Credit Code: 91310115MA7KPP1760
-
Enterprise Type: Limited Partnership
-
General Partner: Suzhou Gaoling Qirui Medical Health Industry Investment Management Co., Ltd.
-
Date of Establishment: 2021-01-19
-
Main Business Address: China (Jiangsu) Suzhou Industrial Park, Suzhou City, Jiangsu Province, No. 183 Taihu Lake Road, Xiaoshan Town, No. 10, Building 2-117
-
Business Scope: General items: Private equity investment fund, venture capital fund management, asset management, and other asset management activities (excluding projects requiring approval according to law, business activities can be independently carried out with business licenses). (Projects requiring approval according to law can be independently carried out after obtaining approval from relevant departments).
- Equity Structure